Uniting Biopharma to Revolutionize Gene Therapy Development & Delivery to the Eye

Revolutionizing Genetic Therapy Development & Delivery to the Eye

The Race Is On; Luxturna Remains the Only Approved Gene Therapy for the Eye, Who Will Be the Next?

The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Join 40+ speakers from the industry leaders in ophthalmic gene therapy such as: Adverum, REGENXBIO, Novartis, Janssen, Kriya, Nanoscope, IVERIC, GenSight, SparingVision, Atsena, AGTC, ViGeneron and many more as we discover novel vector engineering, disease models, clinical trials design, patient enrolment platforms and more.

This year an additional day to compliment the scientific program has been added. The NEW hotly anticipated post-conference delivery day will address the devices and technology involved in the delivery of these drugs. Additionally, our beloved pre-conference workshop day now has four thought-provoking workshops, covering topics that lend better to longer, more interactive discussions such as: non-viral modalities & US & EU regulatory considerations.

Join 150+ stake holders within the industry to overcome these challenges and get these drugs to the ophthalmic gene therapy patients who needs them as fast as possible. Download full event guide here.

World-Class Speaker Faculty Included

Abraham Scaria

Chief Scientific Offier


Ashwath Jayagopal

Chief Scientific Officer

Opus Genetics

Catherine O’Riordan

Head Translational Cluster, Genomics Unit


Daniel Chung

Chief Medical Officer


Hemant Khanna

Vice President of Preclinical Ocular Research


Shannon Boye

Founder & Director

Atsena Therapeutics

Richard Beckman

Chief Medical Officer


Stylianos Michalakis

Co-founder & Chief Scientific Advisor


Theresa Heah

President & Chief Medical Officer

Kriya Ophthalmology

William Beltran

Director, Division of Experimental Retinal Therapies

University of Pennsylvania

Partnerships Included

Snapshot of Attended Companies

Gene Therapy for Ophthalmic Disorders Companies Attending

Other Events in the Gene Therapy Series